{
  "ticker": "PTX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971408",
  "id": "02971408",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250722",
  "time": "0944",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250722/pdf/06m0p6m19n3jth.pdf",
  "summary": "**Summary of ASX Announcement \u2013 Prescient Therapeutics (ASX: PTX)**  \n\n- **Share Purchase Plan (SPP) Extension**:  \n  - Closing date extended from **22 July 2025** to **25 July 2025** (5:00 PM AEST).  \n  - Reason: Shareholder requests for additional time.  \n\n- **SPP Key Details**:  \n  - **Price**: $0.040/share (16.7% discount to 15-day VWAP prior to announcement).  \n  - **Eligibility**: Shareholders registered as of **30 June 2025** (Record Date).  \n  - **Maximum Subscription**: $30,000 per eligible shareholder.  \n\n- **Revised Timetable**:  \n  - **SPP Results Announcement**: 31 July 2025.  \n  - **Shares Issued**: 4 August 2025.  \n  - **Trading Commences**: 5 August 2025.  \n\n- **Additional Material Note**:  \n  - First U.S. site initiation for Phase 2b study highlighted as a milestone (briefing on 22 July).  \n\n*Omitted: Operational pipeline details, director participation, generic disclaimers.*",
  "usage": {
    "prompt_tokens": 2875,
    "completion_tokens": 254,
    "total_tokens": 3129,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T00:51:54.988712"
}